FAP-2286 is under clinical development by Clovis Oncology and currently in Phase II for Adenoid Cystic Carcinoma (ACC). According to GlobalData, Phase II drugs for Adenoid Cystic Carcinoma (ACC) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the FAP-2286 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FAP-2286 overview
3B-201 is under development for the treatment of solid tumors including colorectal cancer, pancreatic ductal adenocarcinoma, adenoid cystic carcinoma, gallbladder cancer, head and neck cancer squamous cell carcinoma, neuroblastoma, soft tissue sarcoma. The drug candidate comprises of PurAffin ligands which are chemically stabilized peptide ligands (peptidomimetics) coupled to a therapeutic radioisotope via a linker and a chelator. The drug candidate is developed based on PurAffin technology. It acts by targeting Fibroblast Activation Protein Alpha (FAP). It is administered through intravenous route.
Clovis Oncology overview
Clovis Oncology (Clovis) is a biopharmaceutical company that develops and commercializes anti-cancer agents in the US and internationally. The company’s lead product includes Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase used for the treatment of adults with BRCA mutation-associated metastatic castrate-resistant prostate cancer. Its major pipeline products include Rucaparib, which is intended for the treatment of ovarian cancer, prostate cancer, gastric cancer, and solid tumors with mutations in homologous recombination repair genes. The company’s preclinical candidate, FAP-2286 is a peptide-targeted radionuclide therapy and imaging agent intended for the treatment of cancer. It operates in California, the US; Cambridge, the UK; and Milan, Italy; among others. Clovis is headquartered in Boulder, Colorado, the US.
For a complete picture of FAP-2286’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
